Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on the development of innovative therapies for cancer and autoimmune diseases. Founded in 2006, Sorrento has made significant strides in the biotechnology sector, particularly in the fields of immunotherapy and antibody development.
The company is renowned for its proprietary antibody platform, which includes unique products such as the COVID-19 therapeutic candidate, COVI-MSC, and various cancer treatment modalities. Sorrento's commitment to advancing healthcare solutions has positioned it as a notable player in the biopharmaceutical industry, with a robust pipeline aimed at addressing unmet medical needs. With operations extending across major regions, Sorrento Therapeutics continues to drive innovation and improve patient outcomes globally.
-20 vs industry average
Sorrento Therapeutics, Inc.’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sorrento Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Sorrento Therapeutics, Inc. yet.
Sorrento Therapeutics, Inc.'s reported carbon emissions
Sorrento Therapeutics, Inc., headquartered in the US, currently does not have any reported carbon emissions data for the most recent year. As such, there are no specific figures available for Scope 1, Scope 2, or Scope 3 emissions. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi).
In the absence of emissions data and reduction commitments, Sorrento Therapeutics, Inc. appears to be in the early stages of addressing its carbon footprint and climate impact. The company may benefit from developing a comprehensive sustainability strategy to align with industry standards and expectations regarding climate action.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sorrento Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Sorrento Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Sorrento Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project